Edwards Lifesciences Company EW is well-poised to develop within the coming quarters owing to its Surgical Structural Coronary heart, which pioneered the RESILIA tissue. The corporate’s Transcatheter Aortic Valve Alternative (“TAVR”) platform is positioned for continued international management and powerful, sustainable development. Additional, the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) enterprise has seen constant development over the previous few quarters, with Edwards effectively scaling its fast-growing companies. In the meantime, macroeconomic impacts and litigation bills could harm its operations.
Up to now 12 months, this Zacks Rank #3 (Maintain) inventory has rallied 13.4% towards the two.1% fall of the trade. The S&P 500 composite has risen 15.2% in the identical time-frame.
The famend international medical gadget firm has a market capitalization of $48.33 billion. Edward Lifesciences’ earnings surpassed estimates in every of the trailing 4 quarters, delivering a median shock of 8.89%.
Let’s delve deeper.
Upsides for EW Inventory
Surgical Structural Coronary heart, a Promising Enterprise: The enterprise pioneered the progressive RESILIA tissue, which is backed by greater than 40 years of the corporate’s tissue expertise management. Within the third quarter of 2025, the section grew 5.3% from the prior-year stage, pushed by sturdy international adoption of Edwards’ premium resilient applied sciences, together with INSPIRIS, MITRIS and KONECT. The corporate continues to see optimistic process development globally for the numerous sufferers handled surgically, together with these present process complicated procedures.
Moreover, administration highlighted sturdy surgical valve efficiency within the current PARTNER III seven-year knowledge. In the meantime, previously few quarters, the corporate made progress in advancing essential improvements worldwide, together with the CE Mark approval for KONECT in Europe and the launch of MITRIS in China.
Picture Supply: Zacks Funding Analysis
TAVR Holds Potential: The TAVR enterprise closed the third quarter of 2025 with 10.6% year-over-year development. Edwards’ sturdy aggressive place and pricing remained steady globally. In america, the scientific conversations across the EARLY TAVR trial knowledge are resulting in a renewed concentrate on streamlining the administration of sufferers with extreme aortic stenosis (AS), enabling nearer follow-up and extra well timed therapy of sufferers with aortic stenosis. In Europe, the broad-based adoption of the SAPIEN platform and the exit of a competitor resulted in a rebalancing of market share and a modest contribution to Edwards’ gross sales.
In Might, the corporate obtained FDA approval for its SAPIEN 3 platform for extreme aortic stenosis (AS) sufferers with out signs, marking the primary FDA approval for TAVR in asymptomatic sufferers. Following the CE Mark for the Alterra system for congenital coronary heart sufferers, Edwards is rolling out this remedy in Europe, and preliminary suggestions from clinicians has been optimistic.
TMTT Portfolio Appears Sturdy: Edwards is on observe for sturdy, sustainable development by means of its development within the long-term TMTT technique, pushed by a rising portfolio of progressive therapies. Within the third quarter, the section witnessed a 53% improve in gross sales in comparison with the prior 12 months, pushed by the sturdy efficiency of each PASCAL and EVOQUE techniques globally. The adoption of differentiated PASCAL expertise is increasing in each new and current websites worldwide.
In the meantime, Edwards is making strides with the EVOQUE industrial rollout, efficiently activating new websites in each america and Europe (aside from preliminary trial facilities). In April, Edwards’ SAPIEN M3 mitral valve substitute system obtained CE Mark for the transcatheter therapy of sufferers with symptomatic mitral regurgitation who’re unsuitable for surgical procedure or transcatheter edge-to-edge (TEER) remedy.
Downsides for EW Inventory
Macro Considerations Put Strain on the Backside Line: Edwards’ intensive international operations and abroad manufacturing amenities and suppliers deliver sure monetary, financial, political and different dangers. The industrywide improve in inflationary strain, provide constraints stemming from geopolitical issues and regulatory adjustments are weighing closely on the corporate’s working outcomes. The enterprise can be at present experiencing staffing shortages throughout the hospital techniques. That is additionally placing important strain on the margins of Edwards. Within the third quarter of 2025, these points resulted in a 31.3% improve in COGS.
Litigation Fees Might Sluggish Down Progress: Lately, Edwards has been concerned in substantial litigation concerning patent and different mental property rights with its opponents. Whatever the consequence, these issues and regulatory actions, remembers or different actions can materially influence its enterprise, fame, and talent to draw and retain prospects.
EW Inventory Estimate Pattern
The Zacks Consensus Estimate for Edwards Lifesciences’ 2025 earnings per share (EPS) has elevated 1 cent to $2.59 previously 30 days.
The Zacks Consensus Estimate for the corporate’s 2025 revenues is pegged at $6.03 billion. This implies a 1% rise from the year-ago reported quantity.
Key Picks
Some better-ranked shares within the broader medical house are BrightSpring Well being Providers BTSG, lllumina ILMN and Insulet PODD.
BrightSpring Well being Serviceshas an estimated long-term earnings development fee of 53.3% in contrast with the trade’s 15.5% development. Its earnings beat the Zacks Consensus Estimate in every of the trailing 4 quarters, with the common shock being 45.1%. BTSG shares have surged 91.5% in contrast with the 1.2% rise previously 12 months.
BTSG sports activities a Zacks Rank #1 (Robust Purchase) at current. You may see the entire listing of at present’s Zacks #1 Rank shares right here.
Illumina, sporting a Zacks Rank #1, has an earnings yield of three.7% in comparison with the trade’s -17.9% yield. Shares of the corporate have dropped 8.6% previously 12 months towards the trade’s 8.6% development. ILMN’s earnings outpaced estimates in three of the trailing 4 quarters and missed on one event, the common shock being 6.7%.
Insulet, carrying a Zacks Rank #2 (Purchase), has a long-term earnings development fee of 29% in comparison with the trade’s 13.2% development. Shares of the corporate have risen 8% towards the trade’s 3.7% fall. PODD’s earnings surpassed estimates in every of the trailing 4 quarters, with the common shock being 17.8%.
Free Report: Making the most of the 2nd Wave of AI Explosion
The subsequent section of the AI explosion is poised to create important wealth for traders, particularly those that get in early. It is going to add actually trillion of {dollars} to the financial system and revolutionize almost each a part of our lives.
Traders who purchased shares like Nvidia on the proper time have had a shot at large beneficial properties.
However the rocket journey within the “first wave” of AI shares could quickly come to an finish. The sharp upward trajectory of those shares will start to stage off, leaving exponential development to a brand new wave of cutting-edge corporations.
Zacks’ AI Growth 2.0: The Second Wave report reveals 4 under-the-radar corporations that will quickly be shining stars of AI’s subsequent leap ahead.
Entry AI Growth 2.0 now, completely free >>
Edwards Lifesciences Company (EW) : Free Inventory Evaluation Report
Illumina, Inc. (ILMN) : Free Inventory Evaluation Report
Insulet Company (PODD) : Free Inventory Evaluation Report
BrightSpring Well being Providers, Inc. (BTSG) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
